

Figure S1. pAkt (Ser473) expression pNET patient tumor samples. IHC staining of pAkt (Ser473) in pNET primary and metastatic tumor samples. Samples were scored on scales of 0-3 for both intensity and distribution percentage and then added together ($n = 39$). Total IHC staining scores are shown in parentheses (nt indicates no tumor).




Figure S2. pAkt (Ser473) inhibition by PKI-402 in NET cell lines at 24h. (A) QGP-1 (left) and BON (right) cells were seeded in a 6-well plate at 800,000 cells per well density and treated with PKI-402 from 50nM to 1,000nM, and collected at 4h. Immunoblotting was performed to confirm PI3K/Akt pathway inhibition at 4h. β-actin was used as a loading control.




Figure S3. Simultaneous PF-04691502 therapy and radiation therapy in NET cell lines. QGP-1

(top) and BON (bottom) cells were seeded in 6-well plate at 800,000 cells per well density and exposed to 4 Gy X-ray radiation. Cells were then immediately treated with PF-04691502 at 500nM or 1,000nM for 24h prior to protein collection. Cleaved-PARP expression was determined by immunoblotting. β -actin was used as a loading control.